About US
Contact us
-
GSK's Zejula FDA oncology AdComm canceled, leaving ovarian cancer nod in Schrodinger's boxThe FDA has decided it no longer needs input from external experts on an ovarian cancer indication for GSK’s Zejula. The oncologic drugs advisory committe2022/11/10
-
Plastics reborn: Inside Novo Nordisk's pre-filled pen recycling pilotThese days, Novo Nordisk is reincarnating many of its spent insulin pens as office furniture like chairs and lamps. It’s an increasinglycommon fatefor the company’s usedinjection devicesunder Novo2022/11/10
-
NICE signs off on Merck's Keytruda for early-stage triple negative breast cancerMonths after offeringMerck’s Keytrudarestricted coverage for previously untreated metastatic triple-negative breast cancer (TNBC), England’s drug cost watchdog has signed off on the drug’s use agains2022/11/8
-
Moderna's Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study saysIt’s been nearly two years since Moderna’s COVID-19 vaccine made its debut in the U.S., but research on the shot is far from over. Now, a new study has flagged higher risks of heart inflammation asso2022/11/8
-
SK bioscience plans global expansion push focused on vaccine manufacturing, gene therapy and moreAmid a global expansion push, SK bioscience has unveiled agrowth strategyfocused on broadeningits reach in vaccine manufacturing and R&D. Going forward, the company plans to focus on respondin2022/11/4
-
Moderna slashes billions from its sales forecast after a quarter of 'pain points'When Modernareacheda deal with the European Commission to delay some shipments of its COVID-19 vaccine to 2023, the company wasn’t certain how the development would affectsales projections for the sh2022/11/4
-
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapiesThe high cost of gene therapies has proved a sticking point for the personalized medicines in recent years, most notably prompting bluebird bio to withdraw its blood disorder treatment Zynteglo in Eu2022/11/2
-
Gilead's Vemlidy enters the pediatric hepatitis B arena with FDA green lightAmid Gilead Science’s oncology push, the company hasn’t forgotten about its hepatitis portfolio. The latest evidence? Gilead's chronic hepatitis B virus (HBV) drug Vemlidy scored a new indication to2022/11/2
-
GSK's Shingrix rebound rolls on with record sales, but looming Zantac lawsuits raise M&A doubtsIn GSK’s first quarter after the Haleon consumer health spinoff, shingles vaccine Shingrix put up another record show. But while a cloud of Zantac lawsuits gathers over the company, CEO Emma Walmsley2022/10/31
-
Alkermes joins Bristol Myers in IL-2 exit with oncology business spinoffInstead of the garden-variety symphony music favored by most pharma companies before entering a conference call, Alkermes selected Fleetwood Mac’s breakup anthem “Go Your Own Way.”2022/10/31